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BACKGROUND
• Despite frequent initial remission, adult and pediatric AML
(pedAML) patients exhibit a high relapse risk, probably due to
therapy-resistant leukemic stem cells (LSC).
• The prognosis of FLT3-ITD mutated patients is extremely poor.
• Current chemotherapeutic regimens perform inadequate
towards LSC eradication.
• The TCRγ chain alternate reading frame protein (TARP) was
identified as an immunotherapeutic target in prostate and breast
adenocarcinoma.
OBJECTIVES
Identify LSC aberrations and develop LSC-targeted strategies
while assuring salvage of normal hematopoietic stem cells (HSC).
RESULTS
CONCLUSIONS
MATERIALS & METHODS
The GSE 17054 micro-array dataset was used for transcriptome
analysis of CD34+CD38- populations sorted from de novo adult
AML (LSC=9) and healthy adults (HSC=4). We next evaluated
transcript expression in CD34+CD38- and CD34+CD38+ sorted
populations from de novo pediatric AML (pedAML) and healthy
controls. First, an 8x60K human gene expression micro-array was
performed in 4 pedAML (2 FLT3 WT, 2 FLT3-ITD) and 3 cord blood
(CB) samples. Second, qPCR was performed in 13 pedAML, 17
adult AML, and 15 healthy controls (7 CB, 6 normal pediatric bone
marrow (NBM) and 2 mobilized blood stem cells (mPBSC), as well
as cell lines of various origin (AML=9, B-ALL=5, CML=1, B-
NHL=2). qPCR data analysis was performed according to the
state-of-the-art and calibrated normalised relative quantities
(CNRQ) were calculated.
Protein expression was evaluated in AML cell lines, including
transgenic TARP-overexpressing and shRNA-induced TARP-
knockdown cell lines, and in pedAML leukemic cells by Western
blotting and confocal microscopy.
TARP-redirected T-cell receptor (TCR)-engineered cytotoxic T-
cells (CTLs) were generated by lenti- (LV) and retroviral (RV)
transduction. Targetability of native and transgenic AML cell lines
and primary patient leukemic cells was examined in vitro by flow
cytometric (FCM) cytotoxicity assays.
• TARP is an AML-specific target expressed in the LSCs and blasts of pediatric and adult AML, while absent in their normal counterparts.
• TARP transcript expression is associated with FLT3-ITD mutations in pedAML. 
• TARP-TCR transgenic CTLs hold great promise as a novel immunotherapeutic strategy in AML.
TARP AS IMMUNOTHERAPEUTIC TARGET IN AML EXPRESSED IN 
THE LSC COMPARTMENT
In the GSE 17054 dataset, TARP was
shown to be most differentially expressed
between adult LSC and HSC (log2-FC
6.92, P<0.01). qPCR analysis of
CD34+CD38+ and CD34+CD38-
fractions confirmed a significant higher
TARP expression in pediatric and adult
leukemic blasts and LSCs compared to
their normal counterparts (Fig.1). In
addition, TARP transcript levels were
significantly increased in AML cell lines
derived from pediatric cases (MV4;11,
THP-1), LSC-enriched cell lines (Kg-1a,
HNT-34) (P<0.001), and HL-60, whereas
negative in B-ALL/NHL and CML.
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The number of patients harboring FLT3-ITD (P<0.001) and HR profiles (P<0.05) were
significantly higher in TARP-high pedAML, whereas TARP-low pedAML patients included
significantly more CBF-leukemia (P<0.01) and SR profiles (P<0.05) (Fig.2A). In adult
AML, high TARP expression was not restricted to FLT3-ITD (Fig.2B).
TARP protein expression was confirmed by Western Blotting in cell lines in
agreement with transcript levels (Fig.3). Confocal microscopy visualised TARP
(red) together with DAPI (blue) and HSP-60 (green, mitochondrial marker). TARP
stained in leukemic cells sorted from a TARP-high pedAML patient, whilst
remaining negative in TARP-low leukemic cells (Fig.4).
Fig.2A.
The lytic response of TARP-TCR CTLs towards WT, transgenic and pulsed
AML cell lines (Fig.5) showed that HLA-A*0201 transgenic AML cell lines were
more efficiently lysed compared to their HLA-A*0201-negative counterparts.
Also, a higher lysis was observed for TARP-transgenic and -pulsed cell lines
compared to their WT. Lysis of leukemic cells from adult AML (n=5) borderline
correlated to TARP transcript levels (Spearman's ρ=0.82, P=0.089).
Fig.1. 
Fig.3. Fig.4.
1. TARP transcript is expressed in adult and pediatric AML blasts and LSC
Fig.2B.
3. TARP protein expression is correlated to transcript levels
2. TARP expression is correlated with a worse prognosis in pedAML
Fig.5.
Legend to Fig.5.
Mean lysis (%) is shown and
whiskers represent ±SEM.
The dashed line indicates
the highest level of non-
TARP mediated background
killing observed for LV
TARP-TCR CTLs, whereas
for RV transduced CTLs,
mock CTLs were
constructed. Positive (+) or
negative (-) expression for
HLA-A*0201 and TARP is
shown between brackets in
this respective order. Bold
symbols indicate the
expression differing from
wild-type (WT), either by
retroviral transduction or
pulsing.
4. TARP and HLA-A*0201 co-expressing cell are killed in vitro by
TARP-TCR CTL
